Salami et al. modified commercially available molecular scores (cell cycle progression score [211], genomic classifier score [212], and genomic prostate score [213]) by including molecular characteristics of the cellular organization (FLNC, GSN, TPM2, and GSTM2), stroma component (BGN, COL1A1, and SFRP4) and others, and showed that scores differed between the different grade groups from different tumor foci from the same patient, highlighting PCa tumor heterogeneity at a transcriptomic level [205]. The gene discussed is SFRP4; the disease is neoplasm.